BIOR Profile
Biora Therapeutics, Inc. is a biotechnology company dedicated to advancing the field of oral biotherapeutics through innovative technologies and therapeutic solutions. The Company is at the forefront of developing ingestible smart capsules that are designed to deliver therapeutics directly to targeted areas within the gastrointestinal (GI) tract. This includes its targeted therapeutics program, which aims to improve the treatment of inflammatory bowel diseases (IBD) by enabling precise drug delivery where it is most needed within the GI tract. Additionally, Biora’s systemic therapeutics program leverages ingestible capsules to provide needle-free delivery of biotherapeutics directly into the intestinal mucosa, enhancing the systemic absorption and therapeutic efficacy of its treatments.
In its pursuit of transforming GI health, Biora Therapeutics is also developing a range of diagnostic devices designed to characterize and diagnose various GI conditions. This includes innovative technologies aimed at diagnosing small intestine bacterial overgrowth and other GI disorders directly at the site of disease. By integrating diagnostic capabilities with therapeutic delivery, Biora aims to provide a comprehensive approach to managing and treating GI diseases, offering both improved diagnosis and targeted treatment options.
The Company, formerly known as Progenity, Inc., rebranded to Biora Therapeutics, Inc. in April 2022 to better reflect its renewed focus on its biotherapeutics pipeline. Since its inception in 2010, Biora has been committed to advancing the science of oral biotherapeutics and diagnostics, with a strategic emphasis on developing technologies that address unmet medical needs in the GI and systemic therapeutic markets. Its innovative approach and commitment to research and development underscore its position as a leader in the biotechnology sector.
Headquartered in San Diego, California, Biora Therapeutics continues to drive forward with its mission of revolutionizing the treatment of gastrointestinal and systemic diseases. The Company’s dedication to integrating advanced diagnostic and therapeutic technologies positions it at the cutting edge of biotherapeutics, aiming to deliver more effective, patient-centric solutions to complex health challenges.
|
